Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review

April 2021 | 56 pages | ID: H5F1FF07344EN
GlobalData

Abstracts

Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded, recombinant formulation of rHuPH20, which enables administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and also with an enhanced resorption of radiopaque agents in subcutaneous urography. It also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. The company works in partnership with Pfizer, Roche, Baxalta, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx for advancing treatment for various cancer types. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

Feb 23,2021: Halozyme reports fourth quarter 2020 results and full year 2020 results
Feb 23,2021: Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
Feb 10,2021: Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
Jan 11,2021: Halozyme provides 2021 financial guidance highlighted by strong revenue and EPS growth
Nov 23,2020: Halozyme raises full year 2020 guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Halozyme Therapeutics Inc - Key Facts
Halozyme Therapeutics Inc - Key Employees
Halozyme Therapeutics Inc - Key Employee Biographies
Halozyme Therapeutics Inc - Major Products and Services
Halozyme Therapeutics Inc - History
Halozyme Therapeutics Inc - Company Statement
Halozyme Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Halozyme Therapeutics Inc - Business Description
Other Break-up: Product Sales, Net
Performance
Other Break-up: Revenue Under Collaborative Agreements
Performance
Other Break-up: Royalties
Performance
Geographical Segment: Belgium
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: The US
Performance
R&D Overview
Halozyme Therapeutics Inc - Corporate Strategy
Halozyme Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Halozyme Therapeutics Inc - Strengths
Halozyme Therapeutics Inc - Weaknesses
Halozyme Therapeutics Inc - Opportunities
Halozyme Therapeutics Inc - Threats
Halozyme Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Halozyme Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 23, 2021: Halozyme reports fourth quarter 2020 results and full year 2020 results
Feb 23, 2021: Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
Feb 10, 2021: Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
Jan 11, 2021: Halozyme provides 2021 financial guidance highlighted by strong revenue and EPS growth
Nov 23, 2020: Halozyme raises full year 2020 guidance
Nov 02, 2020: Halozyme reports third quarter 2020 results and raises full year 2020 guidance
Oct 06, 2020: argenx expands capabilities in antibody engineering through key technology partnerships
Aug 10, 2020: Halozyme reports significant recent achievements and second quarter 2020 results
May 11, 2020: Halozyme reports first quarter 2020 results
Feb 24, 2020: Halozyme announces CFO transition

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Halozyme Therapeutics Inc, Key Facts
Halozyme Therapeutics Inc, Key Employees
Halozyme Therapeutics Inc, Key Employee Biographies
Halozyme Therapeutics Inc, Major Products and Services
Halozyme Therapeutics Inc, History
Halozyme Therapeutics Inc, Subsidiaries
Halozyme Therapeutics Inc, Key Competitors
Halozyme Therapeutics Inc, Ratios based on current share price
Halozyme Therapeutics Inc, Annual Ratios
Halozyme Therapeutics Inc, Annual Ratios (Cont...1)
Halozyme Therapeutics Inc, Annual Ratios (Cont...2)
Halozyme Therapeutics Inc, Interim Ratios
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Halozyme Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Halozyme Therapeutics Inc, Performance Chart (2016 - 2020)
Halozyme Therapeutics Inc, Ratio Charts
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021